ArticleOpen forum infectious diseases2025
Impact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-CD20 therapy has been associated with severe pneumonia in coronavirus disease 2019 (COVID-19) patients. This study aimed to evaluate the impact of anti-CD20 therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related outcomes using a nationwide cohort. Methods: We used the K-CoV-N database, integrating the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Adults (≥19 years) diagnosed with conditions warranting anti-CD20 therapy from January 2020 to December 2021 were included. Patients initiating rituximab (RTX) during the study period were defined as RTX users, whereas RTX nonusers were selected through propensity score matching. Logistic regression analyses were used to estimate the association between RTX use and SARS-CoV-2 infection, as well as COVID-19-related outcomes. Results: Among 1 548 038 patients requiring anti-CD20 therapy, 1 457 171 were vaccinated and 90 867 were unvaccinated. In the vaccinated group, RTX use was not significantly associated with an increased risk of SARS-CoV-2 infection (adjusted odds ratio [aOR] 1.75; 95% confidence interval [CI], .82-3.72; Conclusions: Using a nationwide dataset, this study found that RTX use is associated with an increased risk of severe COVID-19 outcomes in vaccinated individuals. Despite rising vaccination rates, clinicians should carefully weigh the risks and benefits of anti-CD20 therapy during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.